Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder

Cancer

Volumn 115, Issue 4, 2009, Pages 792-799

  Weight, Christopher J ^a   Garcia, Jorge A ^a,b   Hansel, Donna E ^a   Fergany, Amr F ^a   Campbell, Steven C ^a,b   Gong, Michael C ^a   Jones, J Stephen ^a   Klein, Eric A ^a   Dreicer, Robert ^a,b   Stephenson, Andrew J ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Cystectomy; Neoadjuvant chemotherapy; Neoadjuvant therapy; Neoplasm staging; Urinary bladder neoplasms

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; METHOTREXATE; PACLITAXEL; VINBLASTINE;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CYSTECTOMY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT INFORMATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE DRUG DOSE; TREATMENT RESPONSE;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COHORT STUDIES; COMBINED MODALITY THERAPY; CYSTECTOMY; DEOXYCYTIDINE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; METHOTREXATE; MIDDLE AGED; MUSCLE NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 60849134836     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24106     Document Type: Article

References (30)

1. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349:859-866.
2. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) metaanalysis collaboration. Ear Urol. 2005; 48:202-205; discussion 205-206.
3. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003; 361: 1927-1934.
4. Herr HW, Dotan Z, Donat SM, Bajorin DF. Defining optimal therapy for muscle invasive bladder cancer. J Urol. 2007; 177:437-443.
5. NoAuthors Listed. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet. 1999; 354:533-540.
6. Millikan R, Dinney C, Swanson D, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC ver sus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol. 2001; 19:4005-4013.
7. Bochner BH, Cho D, Herr HW, Donat M, Kattan MW, Dalbagni G. Prospectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping. J Urol. 2004; 172(4 pt 1):1286-1290.
8. Greene FL, Page DI, Fleming ID, et al. Amerian Joint Committe on Cancer: AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag, 2002.
9. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 2006; 176(6 pt l):24l4-2422; discussion 2422.
10. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1, 054 patients. J Clin Oncol. 2001; 19:666-675.
11. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005; 23:4602-4608.
12. von der Maase H, Hansen SW, Roberts JT, et al. Gemcita- bine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multi- center, phase III study. J Clin Oncol. 2000; 18:3068-3077.
13. Leissner J, Ghoneim MA, Abol-Enein H, et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol. 2004; 171:139-144.
14. Greene FL, Page DL, Fleming ID, et al., editors. AJCC cancer staging manual, 6th ed. New York: Springer-Verlag, 2002.
15. Mahmud SM, Fong B, Fahmy N, Tanguay S, Aprikian AG. Effect of preoperative delay on survival in patients with bladder cancer undergoing cystectomy in Quebec: a population based study. JUrol. 2006; 175:78-83; discussion 83.
16. Sanchez-Ortiz RF, Huang WC, Mick R, Van Arsdalen KN, Wein AJ, Malkowicz SB. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystec- tomy is associated with worse outcome in bladder carcinoma. J Urol. 2003; 169:110-115; discussion 115.
17. Lara PN, Goldman B, de Vere White R, et al. A sequential treatment approach to muscle-invasive urothelial cancer: a phase II Southwest Oncology Group Trial (S0219) of neoadjuvant paclitaxel, carboplatin, and gemcitabine (PCG) [abstract]. J Clin Oncol. 2008; 26(15Suppl):255s. Abstract 5022.
18. Smith DC, Mackler NJ, Dunn RL, et al. Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. J Urol. 2008; 180:2384-2388; discussion 2388.
19. Dash A, Pettus JA, Herr HW, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial car-cinoma of the bladder: a retrospective experience. Cancer. 2008; 113:2471-2477.
20. Sternberg CN, Yagoda A, Scher HI, et al. M-VAC (metho-trexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. JUrol. 1988; 139:461-469.
21. Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990; 8:1050-1055.
22. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with met- astatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992; 10:1066-1073.
23. Bellmunt J, Von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcita- bine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/ Intergroup Study [abstract]. J Clin Oncol. 2007; 25: (18 Suppl):242s. Abstract LBA5030.
24. Kaufman D, Raghavan D, Carducci M, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. JClin Oncol. 2000; 18:1921-1927.
25. Stadler WM, Hayden A, von der Maase H, et al. Long- term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol. 2002; 7: 153-157.
26. Moore MJ, Winquist EW, Murray N, et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. JClin Oncol. 1999; 17:2876-2881.
27. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999; 17:3173-3181.
28. Herr HW, Donat SM, Bajorin DF. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol. 2001; 165:811-814.
29. von der Maase H, Andersen L, Crino L, Weinknecht S, Dogliotti L. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. Ann Oncol. 1999; 10:1461-1465.
30. Weizer AZ, Joshi D, Daignault S, et al. Performance status is a predictor of overall survival of elderly patients with muscle invasive bladder cancer. J Urol. 2007; 177:1287-1293.